HRP20120633T1 - Formulacija rasagilina s odgođenim oslobađanjem - Google Patents
Formulacija rasagilina s odgođenim oslobađanjem Download PDFInfo
- Publication number
- HRP20120633T1 HRP20120633T1 HRP20120633AT HRP20120633T HRP20120633T1 HR P20120633 T1 HRP20120633 T1 HR P20120633T1 HR P20120633A T HRP20120633A T HR P20120633AT HR P20120633 T HRP20120633 T HR P20120633T HR P20120633 T1 HRP20120633 T1 HR P20120633T1
- Authority
- HR
- Croatia
- Prior art keywords
- rasagiline
- dosage form
- taken
- pharmaceutically acceptable
- citrate
- Prior art date
Links
- RUOKEQAAGRXIBM-GFCCVEGCSA-N rasagiline Chemical compound C1=CC=C2[C@H](NCC#C)CCC2=C1 RUOKEQAAGRXIBM-GFCCVEGCSA-N 0.000 title claims abstract 21
- 229960000245 rasagiline Drugs 0.000 title claims abstract 21
- 230000003111 delayed effect Effects 0.000 title 1
- 238000009472 formulation Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 239000011248 coating agent Substances 0.000 claims abstract 10
- 238000000576 coating method Methods 0.000 claims abstract 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims abstract 7
- 239000002253 acid Substances 0.000 claims abstract 6
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract 4
- 239000006186 oral dosage form Substances 0.000 claims abstract 3
- 239000002552 dosage form Substances 0.000 claims 15
- 239000000454 talc Substances 0.000 claims 7
- 235000012222 talc Nutrition 0.000 claims 7
- 229910052623 talc Inorganic materials 0.000 claims 7
- 229920001577 copolymer Polymers 0.000 claims 5
- GDCRSXZBSIRSFR-UHFFFAOYSA-N ethyl prop-2-enoate;2-methylprop-2-enoic acid Chemical compound CC(=C)C(O)=O.CCOC(=O)C=C GDCRSXZBSIRSFR-UHFFFAOYSA-N 0.000 claims 5
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 5
- 229920000881 Modified starch Polymers 0.000 claims 4
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 claims 4
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims 4
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims 4
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims 4
- 229960003943 hypromellose Drugs 0.000 claims 4
- 239000001069 triethyl citrate Substances 0.000 claims 4
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 claims 4
- 235000013769 triethyl citrate Nutrition 0.000 claims 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 3
- 229930195725 Mannitol Natural products 0.000 claims 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 3
- 229920002472 Starch Polymers 0.000 claims 3
- 235000021355 Stearic acid Nutrition 0.000 claims 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims 3
- 239000000594 mannitol Substances 0.000 claims 3
- 235000010355 mannitol Nutrition 0.000 claims 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 3
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims 3
- 239000004014 plasticizer Substances 0.000 claims 3
- 239000008107 starch Substances 0.000 claims 3
- 235000019698 starch Nutrition 0.000 claims 3
- 239000008117 stearic acid Substances 0.000 claims 3
- 229910002012 Aerosil® Inorganic materials 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 1
- 206010021518 Impaired gastric emptying Diseases 0.000 claims 1
- 102000010909 Monoamine Oxidase Human genes 0.000 claims 1
- 108010062431 Monoamine oxidase Proteins 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 239000012736 aqueous medium Substances 0.000 claims 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 claims 1
- 239000012535 impurity Substances 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000036186 satiety Effects 0.000 claims 1
- 235000019627 satiety Nutrition 0.000 claims 1
- 238000005303 weighing Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2893—Tablet coating processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
- C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
- C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Stabilni oralni oblik doziranja, naznačen time, da se sastoji od jezgre koja ima rasagilin citrat i barem jedan farmaceutski prihvatljiv ekscipijent, te od farmaceutski prihvatljive obloge otporne na kiselinu. Patent sadr·i jo® 9 patentnih zahtjeva.
Claims (10)
1. Stabilni oralni oblik doziranja, naznačen time, da se sastoji od jezgre koja ima rasagilin citrat i barem jedan farmaceutski prihvatljiv ekscipijent, te od farmaceutski prihvatljive obloge otporne na kiselinu.
2. Stabilni oralni oblik doziranja prema patentnom zahtjevu 1 težine manje od 150 mg, naznačen time, da se jezgra sastoji u biti od barem jednog farmaceutski prihvatljivog ekscipijenta i rasagilin citrata, kod čega barem jedan farmaceutski prihvatljiv ekscipijent u jezgri jest barem jedan antioksidans i barem jedan dezintegrator, kod čega je antioksidans prvenstveno limunska kiselina, a dezintegrator je u jezgri prvenstveno prisutan u količini između 0,5 tež.% i 20 tež.%, a kod čega dezintegrator prvenstveno jest prethodno želatinirani škrob.
3. Oblik doziranja prema patentnom zahtjevu 2, naznačen time, da je sadržaj rasagilin citrata od 0,74 mg do 3,63 mg i koji uz rasagilin citrat sadrži manitol, koloidni silicijev dioksid, škrob NF, prethodno želatinirani škrob, stearinsku kiselinu, talk, hipromelozu, kopolimer metakrilna kiselina - etil akrilat, ekstra fini talk i trietil citrat.
4. Oblik doziranja prema bilo kojem od patentnih zahtjeva 1-3, naznačen time, da farmaceutski prihvatljiva obloga otporna na kiselinu sadrži kopolimer metakrilna kiselina - etil akrilat (1:1) i plastifikator,
kod čega je omjer kopolimera metakrilna kiselina - etil akrilat (1:1) prema plastifikatoru prvenstveno između 10 prema 1 i 2 prema 1, pogodnije oko 5 prema 1,
kod čega plastifikator jest trietil citrat,
kod čega farmaceutski prihvatljiva obloga otporna na kiselinu nadalje sadrži talk,
kod čega farmaceutski prihvatljiva obloga otporna na kiselinu jest između 3 tež.% i 12 tež.% oblika doziranja, prvenstveno oko 8 tež.% oblika doziranja, ili kod čega farmaceutski prihvatljiva obloga otporna na kiselinu sadrži dva sloja obloge, a prvenstveno onaj unutarnji od dva sloja obloge sadrži hipromelozu.
5. Oblik doziranja prema bilo kojem od patentnih zahtjeva 1-4,
naznačen time, da oslobađa između 80 i 100% rasagilina kada ga se stavi u aparat s okretnom košaricom u 500 ml puferiranog vodenog medija pH 6,8 kod 37oC pri 75 okretaja u minuti tijekom 20 minuta,
koji, kada ga uzme čovjek, dostiže u biti istu MAO-B inhibiciju kao što je ona od odgovarajućeg doziranja rasagilina uzetog kao formulacija za trenutno oslobađanje,
koji oblik doziranja, kada ga uzme čovjek, daje AUC (površina ispod krivulje) vrijednost rasagilina od 80-130%, prvenstveno 80-125% od one odgovarajuće količine rasagalina uzetog kao formulacija za trenutno oslobađanje,
koji oblik doziranja, kada ga uzme čovjek u stanju sitosti, daje AUC vrijednost rasagilina koja je veća od one odgovarajuće količine rasagilina uzetog kao formulacija za trenutno oslobađanje,
koji oblik doziranja kada ga uzme čovjek, daje Cmax rasagilina 80-145%, prvenstveno 80-125% od one odgovarajuće količine rasagilina uzetog kao formulacija za trenutno oslobađanje, ili
koji oblik doziranja kada ga uzme čovjek u stanju sitosti daje Cmax rasagilina koji je veći od odgovarajuće količine rasagilina uzetog kao formulacija za trenutno oslobađanje.
6. Oblik doziranja prema bilo kojem od patentnih zahtjeva 1-3, naznačen time, da je jezgra u obliku tablete, kod čega je sadržaj rasagilina 1,0 mg, a tableta sadrži 45,0 mg manitola, 0,4 mg aerosila, 5,0 mg škroba NF, 20,0 mg prethodno želatiniranog škroba, 1,5 mg stearinske kiseline, 1,5 mg talka, 3,5 mg hipromeloze, 4,0 mg kopolimera metakrilna kiselina - etil akrilat, 0,8 mg trietil citrata, 1,9 mg ekstra finog talka i 2,0 mg agensa za boju obloge.
7. Oblik doziranja prema bilo kojem od patentnih zahtjeva 1-3, naznačen time, da je jezgra u obliku tablete, kod čega je sadržaj rasagilina 0,5 mg, a tableta sadrži 45,5 mg manitola, 0,4 mg aerosila, 5,0 mg škroba NF, 20,0 mg prethodno želatiniranog škroba, 1,5 mg stearinske kiseline, 1,5 mg talka, 3,5 mg hipromeloze, 4,0 mg kopolimera metakrilna kiselina - etil akrilat, 0,8 mg trietil citrata, 1,9 mg ekstra finog talka i 2,0 mg agensa za boju obloge.
8. Oblik doziranja prema bilo kojem od patentnih zahtjeva 1-7, naznačen time, da je ukupna količina nepolarnih onečišćenja manja od 0,3 tež.% u odnosu na količinu rasagilina, ili kod čega je u obliku doziranja količina od N-(2-kloroalil)-1(R)-aminoindana manja od 20 ppm, prvenstveno manja od 4 ppm u odnosu na količinu rasagilina.
9. Oblik doziranja prema bilo kojem od patentnih zahtjeva 1-8, naznačen time, da rasagilin citrat jest monorasagilin citrat.
10. Oblik doziranja prema bilo kojem od patentnih zahtjeva 1-9, naznačen time, da je za uporabu u liječenju čovjeka pogođenog Parkinsonovom bolesti, kod čega čovjek opcionalno pati od odloženog pražnjenja želuca, ili je čovjek opcionalno u stanju sitosti.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20583309P | 2009-01-23 | 2009-01-23 | |
| US12/456,029 US20100189790A1 (en) | 2009-01-23 | 2009-06-09 | Delayed release rasagiline formulation |
| US12/455,976 US8080584B2 (en) | 2009-01-23 | 2009-06-09 | Delayed release rasagiline citrate formulation |
| US12/456,031 US20100189788A1 (en) | 2009-01-23 | 2009-06-09 | Delayed release rasagiline base formulation |
| US12/456,001 US20100189791A1 (en) | 2009-01-23 | 2009-06-09 | Delayed release rasagiline malate formulation |
| US12/689,044 US7855233B2 (en) | 2009-01-23 | 2010-01-18 | Citrate salt of Rasagiline |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120633T1 true HRP20120633T1 (hr) | 2012-09-30 |
Family
ID=42354337
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110745T HRP20110745T1 (hr) | 2009-01-23 | 2011-10-13 | Formulacija rasagilina s odgođenim oslobađanjem |
| HRP20120633AT HRP20120633T1 (hr) | 2009-01-23 | 2012-08-02 | Formulacija rasagilina s odgođenim oslobađanjem |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110745T HRP20110745T1 (hr) | 2009-01-23 | 2011-10-13 | Formulacija rasagilina s odgođenim oslobađanjem |
Country Status (22)
| Country | Link |
|---|---|
| US (9) | US20100189791A1 (hr) |
| EP (3) | EP2381767B1 (hr) |
| JP (2) | JP5774495B2 (hr) |
| CN (1) | CN102333442B (hr) |
| AR (1) | AR075148A1 (hr) |
| AT (3) | ATE556703T1 (hr) |
| AU (1) | AU2010206970B2 (hr) |
| CA (3) | CA2713292C (hr) |
| CY (2) | CY1112486T1 (hr) |
| CZ (1) | CZ22819U1 (hr) |
| DE (1) | DE202010017129U1 (hr) |
| DK (3) | DK2246321T3 (hr) |
| EA (1) | EA029262B1 (hr) |
| ES (3) | ES2564317T3 (hr) |
| HK (1) | HK1150308A1 (hr) |
| HR (2) | HRP20110745T1 (hr) |
| IL (1) | IL214220A (hr) |
| PL (2) | PL2246321T3 (hr) |
| PT (2) | PT2308477E (hr) |
| RS (2) | RS52033B (hr) |
| SI (2) | SI2246321T1 (hr) |
| WO (1) | WO2010085354A1 (hr) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005269416B2 (en) * | 2004-07-26 | 2011-07-28 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
| ZA200704917B (en) * | 2004-11-24 | 2008-11-26 | Teva Pharma | Rasagiline orally disintegrating compositions |
| WO2007098264A2 (en) * | 2006-02-21 | 2007-08-30 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| WO2007117431A2 (en) * | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
| EP1892233A1 (de) | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| ES2375761T3 (es) * | 2006-12-14 | 2012-03-06 | Teva Pharmaceutical Industries Ltd. | Base de rasagilina cristalina sólida. |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| CA2698695A1 (en) * | 2007-09-05 | 2009-03-12 | Teva Pharmaceutical Industries Ltd. | Method of treating glaucoma using rasagiline |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| NZ586025A (en) * | 2008-01-11 | 2012-08-31 | Teva Pharma | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate |
| AU2009258120B2 (en) * | 2008-06-10 | 2014-11-27 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
| EP2296462A4 (en) * | 2008-06-13 | 2011-06-15 | Teva Pharma | RASAGILINE FOR INFLUENCING MORBUS PARKINSON |
| JP2011525489A (ja) * | 2008-06-19 | 2011-09-22 | テバ ファーマシューティカル インダストリーズ リミティド | ラサリジン塩基の精製方法 |
| JP2011524907A (ja) * | 2008-06-19 | 2011-09-08 | テバ ファーマシューティカル インダストリーズ リミティド | 固体ラサギリン塩基を調製および乾燥する方法 |
| US20100189791A1 (en) * | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| ITPR20090047A1 (it) * | 2009-06-16 | 2010-12-17 | Agricola Cerasaro S S Soc | Procedimento per la produzione di un trito o crema di aglio e trito o crema di aglio cosi' ottenuta |
| JP2012532843A (ja) | 2009-07-09 | 2012-12-20 | ラティオファーム ゲーエムベーハー | ラサギリンの塩およびその製剤 |
| US9675566B2 (en) | 2009-07-16 | 2017-06-13 | Pathologica Llc | Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing |
| WO2011042812A1 (en) * | 2009-10-09 | 2011-04-14 | Stefan Lorenzl | Use of rasagiline for the treatment of progressive supranuclear palsy |
| CN102048717B (zh) | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
| WO2011087791A1 (en) * | 2009-12-22 | 2011-07-21 | Teva Pharmaceutical Industries Ltd. | 3-keto-n-propargyl-1-aminoindan |
| US8569379B2 (en) | 2010-07-27 | 2013-10-29 | Teva Pharmaceutical Industries Ltd. | Use of rasagiline for the treatment of olfactory dysfunction |
| US8691872B2 (en) | 2010-07-27 | 2014-04-08 | Teva Pharmaceutical Industries Ltd. | Dispersions of rasagiline citrate |
| EP2632254A4 (en) * | 2010-10-26 | 2015-08-05 | Teva Pharma | RASAGILIN ENRICHED IN DEUTERIUM |
| HU231054B1 (hu) * | 2010-11-18 | 2020-04-28 | Egis Gyógyszergyár Nyrt. | Gyógyászati készítmény előállítására alkalmazható új sók |
| ES2662373T3 (es) | 2011-01-19 | 2018-04-06 | Pathologica, Llc. | Formas de dosificación farmacéutica oral de liberación controlada que comprenden MGBG |
| AU2012323351A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | R(+)-N-methyl-propargyl-aminoindan |
| BR112014008555A2 (pt) | 2011-10-10 | 2017-04-18 | Teva Pharma | r(+)-n-formil-propargil-aminoindano |
| MX2014004196A (es) * | 2011-10-10 | 2014-05-28 | Teva Pharma | Citramida de rasagilina. |
| EP2827848B1 (en) | 2012-03-21 | 2016-04-27 | Synthon BV | Stabilized pharmaceutical compositions comprising rasagiline salts |
| BR112015003451A2 (pt) * | 2012-08-17 | 2017-07-04 | Teva Pharma | formulação parentérica de rasagilina |
| JP2014050039A (ja) * | 2012-09-03 | 2014-03-17 | Sony Corp | 画像処理装置、画像処理方法及びコンピュータプログラム |
| EP3831372A1 (en) | 2013-01-08 | 2021-06-09 | Pathologica LLC | Mitoguazone for preventing the relapse or the progression of multiple sclerosis |
| JP6173098B2 (ja) | 2013-07-30 | 2017-08-02 | キヤノン株式会社 | 光学機器 |
| JP5897196B1 (ja) | 2015-10-05 | 2016-03-30 | 大同化成工業株式会社 | 糖又は糖アルコール、膨潤型結合剤、崩壊剤及び高吸収性賦形剤を含む複合化造粒物及びその製造方法 |
| CN107049985B (zh) * | 2017-06-07 | 2020-06-19 | 广州帝奇医药技术有限公司 | 一种抗帕金森病药物的长效缓释制剂及其制备方法 |
| CN109028765A (zh) * | 2018-07-02 | 2018-12-18 | 无锡富泽药业有限公司 | 一种盐酸替罗非班的干燥方法 |
| CN109832262A (zh) * | 2019-01-25 | 2019-06-04 | 袁隆平农业高科技股份有限公司 | 活体植物保存方法 |
| US20230414499A1 (en) | 2020-10-23 | 2023-12-28 | Sph Zhongxi Pharmaceutical Co., Ltd. | Sublingual film dosage of rasagiline or pharmaceutically acceptable salt thereof, and preparation method therefor and use thereof |
| CN115400090A (zh) * | 2022-10-09 | 2022-11-29 | 北京新领先医药科技发展有限公司 | 一种雷沙吉兰的口崩片组合物及其制备方法 |
Family Cites Families (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US761917A (en) * | 1903-02-11 | 1904-06-07 | Alphonse King | Telegraph-transmitter. |
| IL92952A (en) * | 1990-01-03 | 1994-06-24 | Teva Pharma | R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them |
| US5744500A (en) * | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
| IL112819A (en) * | 1991-10-16 | 2001-11-25 | Teva Pharma | Fluorinated 1-aminoindan compounds and a process for their preparation |
| IL111240A (en) | 1993-10-18 | 2001-10-31 | Teva Pharma | Salts of r(+) - enantiomers of n- propargyl-1-aminoindan and pharmaceutical compositions comprising them |
| IL115357A (en) * | 1995-09-20 | 2000-01-31 | Teva Pharma | Stable compositions containing N-propargyl-1-aminoindan and polyhydric alcohols |
| US5663415A (en) * | 1996-06-28 | 1997-09-02 | Jame Fine Chemicals, Inc. | Process for preparing antihistamine tannates |
| IL118836A (en) * | 1996-07-11 | 2001-01-11 | Teva Pharma | Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan |
| DE69732984T2 (de) * | 1996-12-18 | 2006-02-16 | Teva Pharmaceutical Industries Ltd. | Aminoindanderivate |
| AU6417198A (en) | 1997-03-13 | 1998-09-29 | Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency | Cytoprotective agents comprising monoamine oxidase inhibitors |
| US6548706B2 (en) * | 1999-12-23 | 2003-04-15 | Aerojet Fine Chemicals Llc | Preparation of 2S,3S-N-isobutyl-N-(2-hydroxy-3-amino-4-phenylbutyl) -p-nitrobenzenesulfonylamide hydrochloride and other derivatives of 2-hydroxy-1,3-diamines |
| DE10041478A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung |
| US20070197484A1 (en) * | 2001-05-03 | 2007-08-23 | Ching Song | Method of treating disorder related to high cholesterol concentration |
| CA2446988A1 (en) | 2001-05-14 | 2002-11-21 | Pfizer Products Inc. | The citrate salt of 5, 8, 14-triazatetracyclo(10.3.1.02,11.04.9)-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
| GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
| BR0214780A (pt) | 2001-12-07 | 2004-11-09 | Pfizer Prod Inc | Sal de ácido cìtrico de um composto terapêutico e composições farmacêuticas deste |
| US7118765B2 (en) | 2001-12-17 | 2006-10-10 | Spi Pharma, Inc. | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms |
| AU2003290838A1 (en) * | 2002-11-15 | 2004-06-15 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline with or without riluzole to treat amyotrophic lateral sclerosis |
| AR044007A1 (es) * | 2003-04-11 | 2005-08-24 | Newron Pharmaceuticals Inc | Metodos para el tratamiento de la enfermedad de parkinson |
| US20060177507A1 (en) * | 2003-05-22 | 2006-08-10 | Joaquina Faour | Controlled release device containing lercanidipine |
| MY144177A (en) | 2004-02-04 | 2011-08-15 | Novartis Ag | Salt forms of 4-(4-methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide. |
| MXPA06009991A (es) * | 2004-03-03 | 2007-04-10 | Teva Pharma | Una composicion farmaceutica estable que comprende un farmaco labil acido. |
| US7145005B2 (en) | 2004-05-12 | 2006-12-05 | Abbott Laboratories | 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation |
| MX2007001058A (es) * | 2004-07-26 | 2007-04-16 | Teva Pharma | Formas de dosificacion con tableta nucleo recubierta entericamente. |
| AU2005269416B2 (en) | 2004-07-26 | 2011-07-28 | Teva Pharmaceutical Industries, Ltd. | Pharmaceutical dosage forms including rasagiline |
| US20060069060A1 (en) | 2004-09-27 | 2006-03-30 | Sanjeev Redkar | Salts of decitabine |
| WO2006057912A2 (en) | 2004-11-24 | 2006-06-01 | Teva Pharmaceutical Industries, Ltd. | Rasagiline orally disintegrating compositions |
| ZA200704917B (en) * | 2004-11-24 | 2008-11-26 | Teva Pharma | Rasagiline orally disintegrating compositions |
| PT1848415E (pt) * | 2005-02-17 | 2013-06-27 | Teva Pharma | Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla |
| AU2006216696B2 (en) * | 2005-02-23 | 2011-08-18 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations of improved content uniformity |
| US8349951B2 (en) | 2005-05-31 | 2013-01-08 | Prc Desoto International, Inc. | Polythioether polymers and curable compositions containing them |
| US20070078172A1 (en) * | 2005-06-16 | 2007-04-05 | Jenrin Discovery | Mao-b inhibitors useful for treating obesity |
| GB0514593D0 (en) | 2005-07-15 | 2005-08-24 | Davy Process Techn Ltd | Process |
| CN101287724B (zh) | 2005-09-19 | 2013-11-06 | 硕腾P有限责任公司 | 经吡咯取代的2-吲哚酮的固态盐形式 |
| FR2891459B1 (fr) * | 2005-09-30 | 2007-12-28 | Flamel Technologies Sa | Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant |
| AU2006316585B2 (en) * | 2005-11-17 | 2012-09-20 | Teva Pharmaceutical Industries, Ltd. | Methods for isolating propargylated aminoindans |
| HUP0501084A2 (en) | 2005-11-23 | 2008-05-28 | Richter Gedeon Nyrt | New pharmaceutical compositions of high effectivity |
| US7572834B1 (en) | 2005-12-06 | 2009-08-11 | Teva Pharmaceutical Industries, Ltd. | Rasagiline formulations and processes for their preparation |
| SA07280004B1 (ar) | 2006-02-02 | 2011-10-29 | استرازينيكا ايه بي | ملح سترات من مركب 2- هيدروكسي –3- [5- (مورفولين –4- يل ميثيل) بيريدين –2- يل] 1h- إندول –5- كربونيتريل سترات |
| WO2007098264A2 (en) * | 2006-02-21 | 2007-08-30 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of multiple system atrophy |
| US20080027087A1 (en) | 2006-02-21 | 2008-01-31 | Ampla Pharmaceuticals, Inc. | CB1 antagonists and inverse agonists |
| CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| WO2007117431A2 (en) * | 2006-04-03 | 2007-10-18 | Teva Pharmaceutical Industries, Ltd. | Use of rasagiline for the treatment of restless legs syndrome |
| WO2008010768A1 (en) | 2006-07-17 | 2008-01-24 | Cereuscience Ab | Method of treating and diagnosing restless legs syndrome and periodic limb movements during sleep and means for carrying out the method |
| EP1892233A1 (de) * | 2006-08-18 | 2008-02-27 | Ratiopharm GmbH | Neue Salze des Wirkstoffs Rasagilin |
| CN1911211B (zh) * | 2006-08-25 | 2010-04-14 | 重庆医药工业研究院有限责任公司 | 雷沙吉兰口服固体制剂 |
| CN100542524C (zh) * | 2006-09-29 | 2009-09-23 | 北京德众万全药物技术开发有限公司 | 一种含有雷沙吉兰的药用组合物 |
| AR063983A1 (es) | 2006-11-28 | 2009-03-04 | Wyeth Corp | Formulacion de liberacion controlada de agonistas y antagonistas de piperazina -piperidina del receptor 5-ht1a que tienen una disolucion intestinal mejorada |
| ES2375761T3 (es) | 2006-12-14 | 2012-03-06 | Teva Pharmaceutical Industries Ltd. | Base de rasagilina cristalina sólida. |
| US8524695B2 (en) * | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
| NZ577623A (en) | 2006-12-14 | 2011-05-27 | Teva Pharma | Tannate salt of rasagiline |
| US7949403B2 (en) | 2007-02-27 | 2011-05-24 | Accelerated Care Plus Corp. | Electrical stimulation device and method for the treatment of neurological disorders |
| JP2010524844A (ja) | 2007-04-26 | 2010-07-22 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 認知症のためのシンナミド化合物 |
| EP1987816A1 (de) * | 2007-04-30 | 2008-11-05 | Ratiopharm GmbH | Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff |
| JP5577012B2 (ja) | 2007-05-03 | 2014-08-20 | 株式会社カネカ | 多層基板およびその製造方法 |
| CA2698695A1 (en) * | 2007-09-05 | 2009-03-12 | Teva Pharmaceutical Industries Ltd. | Method of treating glaucoma using rasagiline |
| US8188149B2 (en) * | 2007-09-17 | 2012-05-29 | Teva Pharmaceutical Industries, Ltd. | Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss |
| CA2708820C (en) | 2007-12-24 | 2016-05-10 | Cipla Limited | Process for the synthesis of propargylated aminoindan derivatives |
| NZ586025A (en) | 2008-01-11 | 2012-08-31 | Teva Pharma | Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate |
| US20090247537A1 (en) | 2008-03-25 | 2009-10-01 | William Dale Overfield | Methods for preventing or treating bruxism using dopaminergic agents |
| EP2271612B1 (en) | 2008-03-31 | 2016-08-10 | Actavis Group PTC EHF | Rasagiline mesylate particles and process for the preparation thereof |
| AU2009258120B2 (en) | 2008-06-10 | 2014-11-27 | Teva Pharmaceutical Industries, Ltd. | Rasagiline soft gelatin capsules |
| EP2296462A4 (en) | 2008-06-13 | 2011-06-15 | Teva Pharma | RASAGILINE FOR INFLUENCING MORBUS PARKINSON |
| JP2011525489A (ja) * | 2008-06-19 | 2011-09-22 | テバ ファーマシューティカル インダストリーズ リミティド | ラサリジン塩基の精製方法 |
| JP2011524907A (ja) * | 2008-06-19 | 2011-09-08 | テバ ファーマシューティカル インダストリーズ リミティド | 固体ラサギリン塩基を調製および乾燥する方法 |
| CN101606923B (zh) | 2008-06-20 | 2013-01-09 | 重庆医药工业研究院有限责任公司 | 一种稳定的控释释放的雷沙吉兰透皮贴片及其制备方法 |
| WO2011012140A2 (en) | 2008-07-11 | 2011-02-03 | Synthon Bv | Polymorphs of rasagiline hydrochloride |
| AR074637A1 (es) | 2008-07-18 | 2011-02-02 | Medichem Sa | Formas de sal de adicion acida de r-(+)-n-propargil-1-aminoindano (es decir , base de rasagilina), un compuesto de formula (1), procesos para prepararlos y aislarlos y usos de los mismos |
| US20100029987A1 (en) * | 2008-07-29 | 2010-02-04 | Dipharma Francis S.R.I. | Crystalline Form of Rasagiline and Process for the Preparation Thereof |
| AU2009275665A1 (en) | 2008-07-30 | 2010-02-04 | Generics [Uk] Limited | Polymorphic form of rasagiline mesylate |
| EP2181980A1 (en) | 2008-10-28 | 2010-05-05 | Chemo Ibérica, S.A. | A process for the preparation of (R)-1-aminoindanes |
| DE102008064061A1 (de) | 2008-12-19 | 2010-06-24 | Ratiopharm Gmbh | Feste Zusammensetzung mit dem Wirkstoff Rasagilin |
| US20100189791A1 (en) | 2009-01-23 | 2010-07-29 | Teva Pharmaceutical Industries, Ltd. | Delayed release rasagiline malate formulation |
| JP2012532843A (ja) | 2009-07-09 | 2012-12-20 | ラティオファーム ゲーエムベーハー | ラサギリンの塩およびその製剤 |
| WO2011009873A2 (en) | 2009-07-20 | 2011-01-27 | Medichem, S.A. | New form of an aminoindan mesylate derivative |
| WO2011010324A1 (en) | 2009-07-23 | 2011-01-27 | Alkem Laboratories Ltd. | Oral pharmaceutical composition of rasagiline and process for preparing thereof |
| WO2011042812A1 (en) * | 2009-10-09 | 2011-04-14 | Stefan Lorenzl | Use of rasagiline for the treatment of progressive supranuclear palsy |
| CN102048717B (zh) * | 2009-10-29 | 2014-02-19 | 重庆医药工业研究院有限责任公司 | 一种稳定的雷沙吉兰组合物 |
| WO2011087791A1 (en) * | 2009-12-22 | 2011-07-21 | Teva Pharmaceutical Industries Ltd. | 3-keto-n-propargyl-1-aminoindan |
-
2009
- 2009-06-09 US US12/456,001 patent/US20100189791A1/en not_active Abandoned
- 2009-06-09 US US12/455,976 patent/US8080584B2/en not_active Expired - Fee Related
- 2009-06-09 US US12/456,029 patent/US20100189790A1/en not_active Abandoned
- 2009-06-09 US US12/456,031 patent/US20100189788A1/en not_active Abandoned
-
2010
- 2010-01-18 US US12/689,044 patent/US7855233B2/en not_active Expired - Fee Related
- 2010-01-21 ES ES10733731.3T patent/ES2564317T3/es active Active
- 2010-01-21 CA CA2713292A patent/CA2713292C/en not_active Expired - Fee Related
- 2010-01-21 AU AU2010206970A patent/AU2010206970B2/en not_active Ceased
- 2010-01-21 CA CA2727899A patent/CA2727899C/en not_active Expired - Fee Related
- 2010-01-21 EP EP10733731.3A patent/EP2381767B1/en active Active
- 2010-01-21 EA EA201170962A patent/EA029262B1/ru not_active IP Right Cessation
- 2010-01-21 CN CN201080009551.4A patent/CN102333442B/zh not_active Expired - Fee Related
- 2010-01-21 WO PCT/US2010/000174 patent/WO2010085354A1/en active Application Filing
- 2010-01-21 US US13/145,989 patent/US20120003310A1/en not_active Abandoned
- 2010-01-21 JP JP2011547964A patent/JP5774495B2/ja not_active Expired - Fee Related
- 2010-01-21 CA CA2799515A patent/CA2799515A1/en not_active Abandoned
- 2010-01-22 DK DK10166534.7T patent/DK2246321T3/da active
- 2010-01-22 RS RS20110487A patent/RS52033B/en unknown
- 2010-01-22 SI SI201030008T patent/SI2246321T1/sl unknown
- 2010-01-22 PL PL10166534T patent/PL2246321T3/pl unknown
- 2010-01-22 SI SI201030050T patent/SI2308477T1/sl unknown
- 2010-01-22 PT PT10186379T patent/PT2308477E/pt unknown
- 2010-01-22 DE DE202010017129U patent/DE202010017129U1/de not_active Expired - Lifetime
- 2010-01-22 EP EP10166534A patent/EP2246321B1/en active Active
- 2010-01-22 PT PT10166534T patent/PT2246321E/pt unknown
- 2010-01-22 ES ES10166534T patent/ES2370980T3/es active Active
- 2010-01-22 AT AT10186379T patent/ATE556703T1/de active
- 2010-01-22 AT AT10166534T patent/ATE518527T1/de active
- 2010-01-22 EP EP10186379A patent/EP2308477B1/en active Active
- 2010-01-22 AR ARP100100139A patent/AR075148A1/es unknown
- 2010-01-22 PL PL10186379T patent/PL2308477T3/pl unknown
- 2010-01-22 AT ATGM76/2011U patent/AT12508U1/de not_active IP Right Cessation
- 2010-01-22 DK DK10186379.3T patent/DK2308477T3/da active
- 2010-01-22 ES ES10186379T patent/ES2389889T3/es active Active
- 2010-01-22 RS RS20120337A patent/RS52421B/en unknown
-
2011
- 2011-01-27 CZ CZ201123855U patent/CZ22819U1/cs not_active IP Right Cessation
- 2011-03-11 DK DKBA201100050U patent/DK201100050U4/da not_active IP Right Cessation
- 2011-05-03 HK HK11104418.3A patent/HK1150308A1/xx not_active IP Right Cessation
- 2011-07-20 IL IL214220A patent/IL214220A/en not_active IP Right Cessation
- 2011-10-13 HR HR20110745T patent/HRP20110745T1/hr unknown
- 2011-10-31 CY CY20111101033T patent/CY1112486T1/el unknown
- 2011-12-23 US US13/336,609 patent/US20120100189A1/en not_active Abandoned
-
2012
- 2012-06-29 US US13/538,715 patent/US20120263789A1/en not_active Abandoned
- 2012-07-31 CY CY20121100679T patent/CY1112954T1/el unknown
- 2012-08-02 HR HRP20120633AT patent/HRP20120633T1/hr unknown
-
2013
- 2013-12-23 US US14/139,212 patent/US20140186514A1/en not_active Abandoned
-
2014
- 2014-11-26 JP JP2014239283A patent/JP2015091813A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120633T1 (hr) | Formulacija rasagilina s odgođenim oslobađanjem | |
| JP2011509295A5 (hr) | ||
| CA2415378C (fr) | Composition pharmaceutique orale a liberation controlee et a absorption prolongee | |
| HRP20180904T1 (hr) | Farmaceutski oblik doziranja koji sadrži 6'-fluoro-(n-metil-ili n,n-dimetil-)-4-fenil-4',9'-dihidro-3'h-spiro[cikloheksan-1,1'-pirano[3,4,b]indol]-4-amin za liječenje neuropatske boli | |
| JP2012515775A5 (hr) | ||
| HRP20140946T1 (hr) | Terapeutske kompozicije koje sadrže rilpivirin hcl i tenovofir dizoproksil fumarat | |
| CA2628200A1 (en) | Solid pharmaceutical compositions containing pregabalin | |
| WO2013076216A1 (en) | Controlled release particles comprising dimethyl fumarate | |
| IL298998B1 (en) | Pharmaceutical formulations of HIF hydroxylase inhibitor | |
| RU2011152105A (ru) | Составы таблеток 3-цианохинолина и их применение | |
| FI3324948T3 (fi) | Monikerroksisia farmaseuttisesti aktiivista yhdistettä vapauttavia mikropartikkeleita nestemäisessä annosmuodossa | |
| ES2781110T3 (es) | Preparación de material compuesto que comprende una capa de recubrimiento de película, que contiene un inhibidor de la 5-alfa-reductasa, y método para la producción de la preparación de material compuesto | |
| WO2018064490A1 (en) | Compositions of midodrine and methods of using the same | |
| EP2994108A1 (en) | Oral pharmaceutical formulation | |
| US20230145374A1 (en) | Non-hormonal compositions and methods for male contraception | |
| CA3008471A1 (en) | Apremilast sustained release preparation | |
| JP2020511419A5 (hr) | ||
| US10842802B2 (en) | Controlled release pharmaceutical dosage forms | |
| US20160074333A1 (en) | Pharmaceutical compositions of tamsulosin or salts thereof | |
| JP2020512292A5 (hr) | ||
| RU2014115289A (ru) | Композиция пазопаниба | |
| JP2009511607A (ja) | エスシタロプラムおよびブプロピオンを含有する安定な医薬製剤 | |
| RU2006104035A (ru) | Твердая лекарственная форма дииндолилметана для лечения неопластических заболеваний | |
| WO2018091609A1 (en) | Formulation comprising 4-methylpyrazole | |
| RU2799756C2 (ru) | Применение композиции для негормональной контрацепции и упаковка |